 The FDA lifted all holds on all CymaBay liver disease studies back in July, since, shares have begun clawing back, 319 upside YTD. The company has presented positive top-line data from the ENHANCE study for Seladelpar, which shows high conversion potential in a complex chronic disease segment. 